RxDoctor Payments DataLook up a doctor →

Jonathan Ownby, MD

Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1780887877

Payments from drug & device makers

$564,817in general payments, 2019–2025

Across 1,766 payments — averaging $319.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$290K
  • AbbVie$211K
  • Merck$14K
  • Amryt Pharma Holdings Ltd$11K
  • Lilly USA, LLC$6K
  • Abbott$6K
  • plus $25K from 54 others
$4,056in research payments, 2019–2025

Across 21 payments — averaging $193.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Corcept Therapeutics$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Corcept Therapeutics304$290,129
AbbVie66$211,308
Merck48$14,193
Amryt Pharma Holdings Ltd35$11,129
Lilly USA, LLC158$6,497
Abbott83$6,199
Chiesi USA, Inc.17$3,148
Novo Nordisk205$2,677
Insulet Corporation35$2,060
Amgen(2 entities)87$1,513
Sanofi-aventis U.S. LLC71$1,474
Xeris Pharmaceuticals, Inc.67$1,415
Aegerion Pharmaceuticals, Inc.4$1,140
Mannkind Corporation78$932
Boehringer Ingelheim55$921
AstraZeneca(2 entities)51$763
Tandem Diabetes Care, Inc.4$763
Novartis35$718
Amneal Pharmaceuticals LLC35$706
BETA Bionics, Inc.15$603
Dexcom, Inc.33$587
Cequr Corporation8$496
Amarin Pharma, Inc.23$438
Senseonics, Incorporated1$400
Radius Health, Inc.16$370
IBSA Pharma Inc.17$316
Bigfoot Biomedical Inc11$315
Zealand Pharma US, Inc.16$302
Medtronic(2 entities)22$281
Madrigal Pharmaceuticals8$245
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$197
Johnson & Johnson14$186
GRT US Holding, Inc.9$179
BD9$169
Bayer8$144
Endo Pharmaceuticals Inc.8$140
Valeritas, Inc.7$139
Averitas Pharma Inc.6$134
Kvk-tech, Inc.8$124
Esperion Therapeutics, Inc.8$121
Lifescan, Inc.7$102
Ipsen Biopharmaceuticals, Inc4$101
Embecta Corp.4$80
Eisai Inc.4$80
Currax Pharmaceuticals LLC5$76
Recordati_rare_diseases_inc.4$62
Astellas Pharma US Inc3$59
Neurocrine Biosciences, Inc.2$56
Ascendis Pharma Endocrinology Inc2$48
Amphastar Pharmaceuticals, Inc.2$45
Shire North American Group Inc3$43
Ascensia Diabetes Care US Inc.3$42
Ultragenyx Pharmaceutical Inc.2$41
Kyowa Kirin, Inc.2$37
Clarus Therapeutics Inc.3$35
Nalpropion Pharmaceuticals LLC2$34
Companion Medical, Inc.1$33
Rhythm Pharmaceuticals, Inc.2$33
Takeda Pharmaceuticals U.S.A., Inc.2$33
Acerus Pharmaceuticals Corporation2$30

How this compares

$564,817 in reported general payments places this provider in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$356,845
Medicare patients
628
Services billed
23,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Atlanta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →